Published in Cancer on January 01, 2005
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol (2009) 1.32
Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics (2010) 0.96
Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag (2006) 0.83
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol (2014) 0.80
Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Cancer (2005) 0.79
Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study. Korean J Intern Med (2006) 0.78
Rapid development of a hepatocellular carcinoma in isolated thrombosis of hepatic veins (classic Budd-Chiari syndrome): case report and review of literature. BMJ Case Rep (2009) 0.77
Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J Gastroenterol (2012) 0.77
Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology. Ecancermedicalscience (2008) 0.75
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clin Transl Gastroenterol (2017) 0.75
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2005) 2.10
Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys (2013) 1.89
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2008) 1.81
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol (2005) 1.79
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg (2011) 1.71
Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol (2012) 1.70
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.61
Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys (2010) 1.60
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 1.57
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (2014) 1.55
Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol (2012) 1.40
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res (2012) 1.39
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys (2008) 1.34
An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol (2012) 1.28
Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer (2010) 1.27
HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol (2012) 1.27
Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys (2011) 1.24
Physiologic and radiographic evidence of the distal edge of the proton beam in craniospinal irradiation. Int J Radiat Oncol Biol Phys (2007) 1.23
Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol (2006) 1.23
Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol (2012) 1.16
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med (2009) 1.12
Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2010) 1.12
Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer (2013) 1.10
Radiation therapy for pediatric central nervous system tumors. J Child Neurol (2009) 1.09
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol (2008) 1.06
Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys (2010) 1.05
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget (2013) 1.03
Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.03
Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer (2008) 1.02
Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer (2011) 1.01
Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys (2008) 1.00
Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol (2013) 1.00
Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy. Int J Radiat Oncol Biol Phys (2013) 1.00
In vivo proton beam range verification using spine MRI changes. Int J Radiat Oncol Biol Phys (2010) 1.00
Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys (2011) 0.99
Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys (2013) 0.93
Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas (2013) 0.93
Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys (2011) 0.92
Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys (2011) 0.92
Radiation dose to the lens during craniospinal irradiation-an improvement in proton radiotherapy technique. Int J Radiat Oncol Biol Phys (2007) 0.92
Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol (2012) 0.92
Novel molecular pathways in Gorham disease: implications for treatment. Pediatr Blood Cancer (2013) 0.91
Changes in cerebral cortex of children treated for medulloblastoma. Int J Radiat Oncol Biol Phys (2007) 0.91
Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab (2007) 0.91
Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Ann Surg Oncol (2012) 0.91
Hyperammonemic encephalopathy in multiple myeloma. N Engl J Med (2002) 0.89
The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors. Phys Med Biol (2014) 0.87
JAK2 mutations and coronary ischemia. N Engl J Med (2010) 0.87
Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Expert Opin Investig Drugs (2007) 0.86
Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol (2008) 0.86
Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol (2012) 0.86
Bifocal intracranial tumors of nongerminomatous germ cell etiology: diagnostic and therapeutic implications. Neuro Oncol (2013) 0.86
Diffuse small-bowel myelomatosis. N Engl J Med (2004) 0.86
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs (2006) 0.85
Proton radiotherapy for solid tumors of childhood. Technol Cancer Res Treat (2012) 0.85
Delayed diagnosis in children with intracranial germ cell tumors. J Pediatr (2013) 0.84
Role of radiation therapy in pediatric cancer. Hematol Oncol Clin North Am (2006) 0.83
The family impacts of proton radiation therapy for children with brain tumors. J Pediatr Oncol Nurs (2012) 0.83
Proton beam therapy following resection for childhood ependymoma. Childs Nerv Syst (2009) 0.82
Dosimetric impact of Acuros XB dose calculation algorithm in prostate cancer treatment using RapidArc. J Cancer Res Ther (2013) 0.82
Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study. J Neurooncol (2013) 0.81
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res (2003) 0.80
Sentinel-node biopsy in melanoma. N Engl J Med (2007) 0.80
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs (2005) 0.80
Case records of the Massachusetts General Hospital. Case 20-2007. An 11-year-old boy with a calcified mass in the nose. N Engl J Med (2007) 0.80
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs (2011) 0.79
The development of Moyamoya syndrome after proton beam therapy. Pediatr Blood Cancer (2014) 0.78
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocr Pract (2016) 0.78
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol (2010) 0.78
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) (2013) 0.77
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. Invest New Drugs (2005) 0.77
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun (2011) 0.77
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Invest New Drugs (2010) 0.77
Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clin Colorectal Cancer (2005) 0.77
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer (2013) 0.76
Elevation of prostaglandin E2 in lung cancer patients with digital clubbing. J Thorac Oncol (2012) 0.76
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.76
Case 2-2012: Dyspnea and rapidly progressive respiratory failure. N Engl J Med (2012) 0.75
Pure red-cell aplasia secondary to antierythropoietin antibodies. N Engl J Med (2003) 0.75
Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer (2015) 0.75
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas (2016) 0.75